Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

7 min read

Connect with Selexis at Upcoming Industry Events to Gain Pivotal Insights on Cell Line Development

Mar 11, 2022 10:32:39 AM

Geneva, Switzerland, March 11, 2022Selexis SA, a JSR Life Sciences company, today announced that its business and scientific leaders will participate at key in-person and virtual conferences throughout the early spring and summer of 2022.

“Connecting with our peers within the scientific and business communities is imperative to enhancing current innovations as well as forging long-standing relationships that will continue to drive our industry forward,” said Roland Hecht, PhD, Chief Business Officer at Selexis. “We look forward to reconnecting and learning from our current and new partners as we continue our critical work to advance their medicines to the clinic and beyond for the patients who are awaiting new treatment options.”

Meet with Selexis representatives to learn more about the company’s SUREtechnology™ Platform of innovative cell line development tools and modular technologies at the following events:

Bioprocess International US West

15 – 17 March 2022, San Diego Convention Center, San Diego, CA (In Person)

Selexis will exhibit with JSR Life Sciences (Booth 224) at the conference.

Learn more about Bioprocess International at:

BIO-Europe Spring 2022

28 – 31 March 2022, (Virtual event)

Selexis will be partnering at the conference.

To schedule a meeting with our BD team, please register for the event.

To learn more about the conference, please visit:


Swiss Biotech Day 2022

2 – 3 May 2022, Conference Center Basel, Switzerland (In Person)

Selexis will exhibit with sister company KBI Biopharma.

To learn more about the conference and to register, please visit:


PEGS US Boston

2 – 6 May 2022, Hynes Convention Center, Boston, MA (In Person)

Selexis will present, sponsor and exhibit (Booth 231) at the conference.

Selexis Bioinformatics Scientist, Emanuel Schmid-Siegert will present “Comprehensive cell-line characterization and genotypic stability”.

To learn more about PEGS Boston, please visit:


Bio Korea 2022

11 – 13 May 2022, Coex, Seoul, South Korea (In Person)

For more information about this conference and to register, please visit:


Bioprocess International Europe

17 – 20 May 2022, Messe Wien Congress Center, Vienna, Austria (In Person and Virtual event)

Selexis will share a booth with JSR Life Sciences.

In addition, Séverine Fagète, PhD, Selexis Vice President, Cell Line Development Services, will present “CHO fed-batch strategies to rapidly increase mAb titers by 100% without sacrificing product quality” on May 19 from 2:30 p.m. – 2:45 p.m. CET.

For more information and to register, please visit:


Antibody Engineering & Therapeutics Europe

7 – 9 June 2022, Postillion Hotel & Convention Center, Amsterdam, The Netherlands (In Person and Virtual)

For more information about this conference and to register, please visit:


BIO International Convention US

13 – 16 June 2022, San Diego, CA

Selexis will exhibit with JSR Life Sciences (Booth 1337 in the BioProcess Zone) and participate in the One-on-One Partnering™ System.

Register for partnering to meet with the BD team.

Schedule a partnering meeting at

For more information about this conference, please visit:


European Society for Animal Cell Technology (ESACT) 27th Meeting

26 – 29 June 2022, Lisbon, Spain

For more information about this conference and to register, please visit:


BioPharma Expo 2022

13 – 15 July 2022, Tokyo Big Sight, Japan (In Person)

For more information and to register, please visit:


Bio Asia-Taiwan Exhibition

28 – 31 July 2022, Taipei Nangang Exhibition Center, Hall 2, 4F, Taiwan.

For more information and to register, please visit:


About Selexis SA

Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 155 drug candidates in preclinical and clinical development and the manufacture of nine commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at

# # #


- Web        
- LinkedIn
- Twitter
- Facebook 

Media Inquiries for Selexis
Mike Beyer
Sam Brown Inc.
+1 312-961-2502

Company Inquiries for Selexis
Robert Meister
Head, Corporate Communications
+1 602-953-1716

Topics: 2022

Press Releases